Valeant Pharmaceuticals International Inc. - Articles and news items

Suicidal ideation

FDA approves new psoriasis drug that induced suicide in trial

Industry news / 17 February 2017 / Niamh Marriott, Digital Editor

The US Food and Drug Administration (FDA) has approved Valeant’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis. Siliq is administered as an injection. Siliq is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light […]

AstraZeneca licenses skin disease drugs to LEO Pharma

Industry news / 1 July 2016 / Victoria White, Digital Content Producer

AstraZeneca has entered into an agreement with LEO Pharma for the global licence to tralokinumab in skin diseases.

Valeant Pharmaceuticals probed on drug pricing

Industry news / 15 October 2015 / Victoria White

Valeant has also revealed that it has responded to a letter from US Senator Claire McCaskill concerning the price of Nitropress and Isuprel…

FDA grants HAE drug Ruconest 12-years of exclusivity

Industry news / 8 October 2015 / Victoria White

The exclusivity ensures that the FDA will not approve any applications for biosimilars of the drug before July 2026…

Valeant to acquire Sprout for $1 billion

Industry news / 20 August 2015 / Victoria White

Valeant has entered into a definitive agreement to acquire Sprout, makers of female libido drug Addyi, for approximately $1 billion…

Janssen Pharmaceuticals Logo

Janssen Pharmaceuticals, Inc. announces definitive agreement to divest Ortho Dermatologics Division

Industry news, News / 15 July 2011 / Janssen Pharmaceuticals Inc

Janssen Pharmaceuticals, Inc. announced a definitive agreement to divest the assets of its Ortho Dermatologics division…

Sanofi Divests Dermik Dermatology Unit to Valeant

Industry news, News / 11 July 2011 / Sanofi

Sanofi announced the strategic divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc…

GlaxoSmithKline logo

GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)

Industry news, News / 13 June 2011 / GlaxoSmithKline

GlaxoSmithKline and Valeant Pharmaceuticals International, Inc. announced that the FDA has approved Potiga™ (ezogabine) Tablets…

Valeant Pharmaceuticals to Acquire PharmaSwiss S.A.

Industry news, News / 1 February 2011 / Valeant Pharmaceuticals International Inc.

Valeant Pharmaceuticals International, Inc. and PharmaSwiss S.A. announced today that they have signed a binding agreement for Valeant to acquire PharmaSwiss…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...